CoChat

The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D)

Open access
Min, Yang Won, Rhee, Poong-Lyul · 2015 · Therapeutic Advances in Gastroenterology

The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.

Abstract

Irritable bowel syndrome (IBS) is a highly prevalent functional bowel disorder. Serotonin (5-HT) is known to play a physiological and pathophysiological role in the regulation of gastrointestinal function. In experimental studies, 5-HT 3 receptor antagonists have been reported to slow colon transit, to blunt gastrocolonic reflex, and to reduce rectal sensitivity. Alosetron and cilansetron, potent and selective 5-HT 3 receptor antagonists, have proven efficacy in the treatment of IBS with diarrhea (IBS-D). However, alosetron was voluntarily withdrawn due to postmarketing reports of ischemic colitis and complications of constipation, and cilansetron was never marketed. Currently alosetron is available under a risk management program for women with severe IBS-D. Ramosetron is another potent and selective 5-HT 3 receptor antagonist, which has been marketed in Japan, South Korea, and Taiwan. In animal studies, ramosetron reduced defecation induced by corticotrophin-releasing hormone and had inhibitory effects on colonic nociception. In two randomized controlled studies including 957 patients with IBS-D, ramosetron increased monthly responder rates of patient-reported global assessment of IBS symptom relief compared with placebo. Ramosetron was also as effective as mebeverine in male patients with IBS-D. In a recent randomized controlled trial with 343 male patients with IBS-D, ramosetron has proved effective in improving stool consistency, relieving abdominal pain/discomfort, and improving health-related quality of life. Regarding safety, ramosetron is associated with a lower incidence of constipation compared with other 5-HT 3 receptor antagonists and has not been associated with ischemic colitis. Although further large prospective studies are needed to assess whether ramosetron is effective for female patients with IBS-D and to evaluate its long-term safety, ramosetron appears to be one of the most promising agents for patients with IBS-D.

Overview

Integrity signals

Registry

Crossref · 10.1177/1756283x15572580

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 48 references

Research works printed but not linked: 1

  1. Bjornsson E., 1998, Am J Physiol, 275, G498

Cited by

See all 31

Metadata

Authors
Min, Y. W., & Rhee, P.-L.
Affiliations
Samsung Medical Center (KR)
Venue
Therapeutic Advances in Gastroenterology
Published
2015-02-24
Volume
8
Issue
3
Pages
136-142
ISSN
  • 1756-283X (ISSN-L)
  • 1756-2848
OpenAlex
W2089464643
Cited by
30
References
49
Citations by year
2026: 2 · 2025: 5 · 2024: 1 · 2023: 4 · 2022: 2 · 2021: 4 · 2020: 2 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 2
FWCI
0.35
Type
journal article
Language
en
Open access
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Therapeutic Advances in Gastroenterology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
Keywords
ramosetron, irritable bowel syndrome with diarrhea, 5-HT3 receptor antagonists, serotonin, alosetron, ischemic colitis, constipation, stool consistency, abdominal pain, health-related quality of life, mebeverine, drug safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D). https://app.cochat.ai/papers/10.1177/1756283x15572580
The paper
Min, Y. W., & Rhee, P.-L. (2015). The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D). Therapeutic Advances in Gastroenterology. https://doi.org/10.1177/1756283x15572580

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.